Concise Review: Prostate Cancer Stem Cells: Current Understanding-Reference-Cited by-同舟云学术

Concise Review: Prostate Cancer Stem Cells: Current Understanding

Published:2018-08-27 Issue:10 Volume:36 Page:1457-1474
ISSN:1066-5099
Container-title:Stem Cells
language:en
Short-container-title:

Author:

Skvortsov Sergej¹²,Skvortsova Ira-Ida¹²,Tang Dean G.³⁴,Dubrovska Anna⁵^ORCID

Affiliation:

1. Laboratory for Experimental and Translational Research on Radiation Oncology (EXTRO-Lab), Department of Therapeutic Radiology and Oncology, Innsbruck Medical University, Innsbruck, Austria

2. Tyrolean Cancer Research Institute, Innsbruck, Austria

3. Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, USA

4. Cancer Stem Cell Institute, Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China

5. OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany, Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology-OncoRay, Dresden, Germany; German Cancer Consortium (DKTK), partner site Dresden, and German Cancer Research Center (DKF

Abstract

Abstract Prostate cancer (PCa) is heterogeneous, harboring phenotypically diverse cancer cell types. PCa cell heterogeneity is caused by genomic instability that leads to the clonal competition and evolution of the cancer genome and by epigenetic mechanisms that result in subclonal cellular differentiation. The process of tumor cell differentiation is initiated from a population of prostate cancer stem cells (PCSCs) that possess many phenotypic and functional properties of normal stem cells. Since the initial reports on PCSCs in 2005, there has been much effort to elucidate their biological properties, including unique metabolic characteristics. In this Review, we discuss the current methods for PCSC enrichment and analysis, the hallmarks of PCSC metabolism, and the role of PCSCs in tumor progression.

Funder

Deutsche Forschungsgemeinschaft

DLR Project Management Agency

BMBF

U.S. National Institutes of Health

Department of Defense

Chinese Ministry of Science and Technology

RPCCC

NCI center

Austrian Science Fund

Austrian National Bank

Ingrid Shaker-Nessmann Cancer Research Foundation